Dr. Scott A. Armstrong, MD, PhD, is Senior Vice President for Drug Discovery and Chief Research Strategy Officer at Dana-Farber Cancer Institute. He is also the David G. Nathan Professor of Pediatrics at Harvard Medical School. Dr. Armstrong’s research group has made seminal discoveries into chromatin based epigenetic mechanisms in cancer, the cells of origin of leukemia, and the biology of various childhood cancers. This work has spurred the development of several new classes of therapeutic agents that target epigenetic mechanisms and gene activity which are being tested in children and adults with cancer. One of these molecules was recently approved by the FDA for the treatment of children and adults with aggressive forms of leukemia. Dr. Armstrong’s work has been recognized with awards such as the Paul Marks Prize for Cancer Research from Memorial Sloan Kettering Cancer Center, the E. Mead Johnson Award from the Society for Pediatric Research, and the Dameshek Prize from the American Society of Hematology. In addition, he is a member of the United States National Academy of Medicine.